November 6, 2008 - AtCor Medical Inc. today introduced the new, lightweight, portable SphygmoCor CP, SphygmoCor CPV and SphygmoCor CPVH systems at Renal Week 2008, the annual scientific meeting of the American Society of Nephrology, Nov. 6-8 and the American Heart Association Scientific Sessions Nov. 9-12.
The company’s SphgymoCor technology is used for noninvasive central blood pressure and pulse wave velocity assessment. SphygmoCor technology is in use in leading medical centers and in clinical trials worldwide, the maker said.
AtCor Medical developed its new, more compact SphygmoCor systems, available in different configurations, to make assessing central blood pressure, pulse wave velocity and heart rate variability easier and more convenient in settings where space is at a premium - at bedside in hospitals, in patient exam rooms in physicians’ offices, ERs, mobile patient screening vans, and in home care. All three tests are used in evaluating cardiovascular status and in managing patient care.
The new SphygmoCor systems, approximately 25 percent the size and weight of AtCor’s first generation systems, offer the same functionality as the earlier SphgymoCor Px and Vx systems with added portability, less power consumption and enhanced electronics. The SphygmoCor CPV system, which performs both central blood pressure and pulse wave velocity assessments, can be also be configured to perform heart rate variability analyses, a new system capability. Heart rate variability testing is used in assessing cardiovascular risk.
A large recently published clinical study found 70 percent of patients with high normal blood pressure had central blood pressures equivalent with those of patients diagnosed with stage one hypertension. Others studies have shown that elevated central pressure is associated with increased risk of heart attack, stroke and kidney disease. Elevated central blood pressure is called a silent killer, because it may go undetected with traditional cuff blood pressure measurements, and studies show it is more than 50 percent more effective as a predictor of cardiovascular events, the company said.
More than 1,700 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies.
For more information: www.atcormedical.com
February 14, 2022 
